It's been a year of game-changing therapy for HCV patients. But the benefits of treatment can only be achieved for those diagnosed. Don't miss out on what these experts have to say.
Ira M. Jacobson, MD
- Vincent Astor Professor of Medicine
- Chief, Division of Gastroenterology
- Â Â and Hepatology
- Medical Director of the Center
- Â Â for the Study of Hepatitis C
- Weill Medical College of
- Â Â Cornell University
- New York, New York
Sherilyn C. Brinkley, MSN, CRNP
- Nurse Practitioner/ Program Manager
- Infectious Disease Department
- Johns Hopkins University
- Baltimore, Maryland
Hashem B. El-Serag, MD, MPH
- Dan L. Duncan Professor of Medicine
- Chief, Section of Gastroenterology and Hepatology
- Baylor College of Medicine
- Michael E. DeBakey VA Medical Center
- Houston, Texas
Nancy S. Reau, MD
- Associate Professor
- Department of Medicine
- University of Chicago
- Chicago, Illinois
Sherilyn C. Brinkley, MSN, CRNP, has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated. Ms. Brinkley's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Hashem B. El-Serag, MD, MPH, has received grant/research support from Abbott Laboratories. Dr. El-Serag's presentation will include no off-label discussion.
Nancy S. Reau, MD, has received honoraria from Merck & Co, Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated; and has received contracted research support from Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated. Dr. Reau's presentation will include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Hashem B. El-Serag, MD, MPH, has received grant/research support from Abbott Laboratories. Dr. El-Serag's presentation will include no off-label discussion.
Ira M. Jacobson, MD, has received grant/research support from Anadys Pharmaceuticals, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; is a consultant for Achillion, Biolex, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; and is on the speakers bureaus of Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc/Schering-Plough, and Roche/Genentech. Dr. Jacobson's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Nancy S. Reau, MD, has received honoraria from Merck & Co, Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated; and has received contracted research support from Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated. Dr. Reau's presentation will include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Available for CME/CE:
Physicians
Publish Date: May 29, 2012 Termination Date: May 28, 2013Nurses
Publish Date: May 29, 2012 Termination Date: May 28, 2013Pharmacists
Publish Date: May 29, 2012 Termination Date: Dec 31, 2012Estimated time for completion of this activity:
CNE: 1.92 hours
CPE: 2.0 hours
Target Audience
This CME/CE activity is designed for hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, pharmacists, and other clinicians involved in the screening and treatment of patients with HCV or those at risk of acquiring the infection.
Activity Goal
The goal of this activity is to provide clinicians with data regarding hepatitis C screening and new direct-acting antiviral (DAA) therapy, as well as practical instruction for integrating screening and DAA therapy into clinical practice.
Learning Objective (s)
- Analyze recent initiatives to increase the awareness of screening and treatment for HCV, the rationale for these initiatives, and practical strategies for their integration into routine clinical practice.
- Evaluate the application of proposed and anticipated HCV screening and treatment guidelines as they relate to delaying the onset of liver disease, improving patient outcomes, and the national goal of disease eradication.
- Formulate and implement treatment strategies using DAAs in clinical practice that optimize the achievement of SVR, as well as strategies to overcome potential barriers to treatment.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 1.92 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 2.0 contact hour (0.2 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-12-1336-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Ira M. Jacobson, MD has received grant/research support from Anadys Pharmaceuticals, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; is a consultant for Achillion, Biolex, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; and is on the speakers bureaus of Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc/Schering-Plough, and Roche/Genentech. Dr. Jacobson's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Sherilyn C. Brinkley, MSN, CRNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated. Ms. Brinkley's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Hashem B. El-Serag, MD, MPH has received grant/research support from Abbott Laboratories. Dr. El-Serag's presentation will include no off-label discussion.
Nancy S. Reau, MD has received honoraria from Merck & Co, Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated; and has received contracted research support from Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated. Dr. Reau's presentation will include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA (Medical Writer) has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Sherilyn C. Brinkley, MSN, CRNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated. Ms. Brinkley's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Hashem B. El-Serag, MD, MPH has received grant/research support from Abbott Laboratories. Dr. El-Serag's presentation will include no off-label discussion.
Ira M. Jacobson, MD has received grant/research support from Anadys Pharmaceuticals, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; is a consultant for Achillion, Biolex, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; and is on the speakers bureaus of Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc/Schering-Plough, and Roche/Genentech. Dr. Jacobson's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Nancy S. Reau, MD has received honoraria from Merck & Co, Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated; and has received contracted research support from Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated. Dr. Reau's presentation will include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: May 29, 2012 Termination Date: May 28, 2013Nurses
Publish Date: May 29, 2012 Termination Date: May 28, 2013Pharmacists
Publish Date: May 29, 2012 Termination Date: Dec 31, 2012Estimated time for completion of this activity:
CNE: 1.92 hours
CPE: 2.0 hours
Target Audience
This CME/CE activity is designed for hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, pharmacists, and other clinicians involved in the screening and treatment of patients with HCV or those at risk of acquiring the infection.
Activity Goal
The goal of this activity is to provide clinicians with data regarding hepatitis C screening and new direct-acting antiviral (DAA) therapy, as well as practical instruction for integrating screening and DAA therapy into clinical practice.
Learning Objective (s)
- Analyze recent initiatives to increase the awareness of screening and treatment for HCV, the rationale for these initiatives, and practical strategies for their integration into routine clinical practice.
- Evaluate the application of proposed and anticipated HCV screening and treatment guidelines as they relate to delaying the onset of liver disease, improving patient outcomes, and the national goal of disease eradication.
- Formulate and implement treatment strategies using DAAs in clinical practice that optimize the achievement of SVR, as well as strategies to overcome potential barriers to treatment.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 1.92 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 2.0 contact hour (0.2 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-12-1336-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Ira M. Jacobson, MD has received grant/research support from Anadys Pharmaceuticals, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; is a consultant for Achillion, Biolex, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; and is on the speakers bureaus of Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc/Schering-Plough, and Roche/Genentech. Dr. Jacobson's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Sherilyn C. Brinkley, MSN, CRNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated. Ms. Brinkley's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Hashem B. El-Serag, MD, MPH has received grant/research support from Abbott Laboratories. Dr. El-Serag's presentation will include no off-label discussion.
Nancy S. Reau, MD has received honoraria from Merck & Co, Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated; and has received contracted research support from Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated. Dr. Reau's presentation will include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA (Medical Writer) has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Sherilyn C. Brinkley, MSN, CRNP has received honoraria from Genentech Inc, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees from Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated. Ms. Brinkley's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Hashem B. El-Serag, MD, MPH has received grant/research support from Abbott Laboratories. Dr. El-Serag's presentation will include no off-label discussion.
Ira M. Jacobson, MD has received grant/research support from Anadys Pharmaceuticals, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; is a consultant for Achillion, Biolex, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, Human Genome Sciences, Merck & Co, Inc/Schering-Plough, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmasset Pharmaceuticals Inc, Roche/Genentech, Tibotec Pharmaceuticals, Vertex Pharmaceuticals Incorporated, and ZymoGenetics Inc; and is on the speakers bureaus of Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc/Schering-Plough, and Roche/Genentech. Dr. Jacobson's presentation may include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Nancy S. Reau, MD has received honoraria from Merck & Co, Inc, and Vertex Pharmaceuticals Incorporated; has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated; and has received contracted research support from Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated. Dr. Reau's presentation will include off-label discussion of anti-HCV drugs and erythropoiesis-stimulating agents.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
It's been a year of game-changing therapy for HCV patients. But the benefits of treatment can only be achieved for those diagnosed. Don't miss out on what these experts have to say.




